Next Article in Journal
Virtual Reality Exercise for Anxiety and Depression: A Preliminary Review of Current Research in an Emerging Field
Previous Article in Journal
Effects of ReadiSorb L-GSH in Altering Granulomatous Responses against Mycobacterium tuberculosis Infection
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
J. Clin. Med. 2018, 7(3), 41; https://doi.org/10.3390/jcm7030041

Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field

Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA
Received: 19 December 2017 / Revised: 19 January 2018 / Accepted: 21 February 2018 / Published: 2 March 2018
Full-Text   |   PDF [232 KB, uploaded 2 March 2018]

Abstract

The ability to create patient derived xenografts (PDXs) has evolved considerably from the breakthrough of the development of immune compromised mice. How researchers in drug discovery have utilized PDX of certain cancer types has also changed from traditionally selecting a few models to profile a drug, to opting to assess inter-tumor response heterogeneity by screening across a broad range of tumor models, and subsequently to enable clinical stratification strategies. As with all models and methodologies, imperfections with this approach are apparent, and our understanding of the fidelity of these models continues to expand. To date though, they are still viewed as one of the most faithful modeling systems in oncology. Currently, there are many efforts ongoing to increase the utility and translatability of PDXs, including introducing a human immune component to enable immunotherapy studies. View Full-Text
Keywords: patient derived xenograft; avatars; mouse clinical trials (MCT); drug discovery; humanized mouse models patient derived xenograft; avatars; mouse clinical trials (MCT); drug discovery; humanized mouse models
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Williams, J.A. Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field. J. Clin. Med. 2018, 7, 41.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top